# A Study to Evaluate GBT021601-012 Single Dose and Multiple Dose in Participants With Sickle Cell Disease (SCD)

> **NCT04983264** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 6 (actual)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** GBT021601

## Key facts

- **NCT ID:** NCT04983264
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-21
- **Primary completion:** 2022-12-06
- **Final completion:** 2022-12-06
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2024-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04983264

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04983264, "A Study to Evaluate GBT021601-012 Single Dose and Multiple Dose in Participants With Sickle Cell Disease (SCD)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04983264. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*